Skip to content 
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. more
| Time Frame | LGND | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 2.14% | 0.91% | -0.82% |
| 1-Month Return | -3.37% | 1.46% | 1.28% |
| 3-Month Return | -8.26% | 3.33% | 3.98% |
| 6-Month Return | 23.93% | 16.03% | 6.73% |
| 1-Year Return | 58.3% | 9.1% | 12.24% |
| 3-Year Return | 167.97% | 21.02% | 72.07% |
| 5-Year Return | 110.14% | 36.15% | 75.69% |
| 10-Year Return | 240.31% | 138.89% | 258.38% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M | [{"date":"2020-12-31","value":67.72,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":81.25,"profit":true},{"date":"2023-12-31","value":54.36,"profit":true},{"date":"2024-12-31","value":69.19,"profit":true}] |
| Cost of Revenue | 30.42M | 62.18M | 52.83M | 35.05M | 11.07M | [{"date":"2020-12-31","value":48.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.96,"profit":true},{"date":"2023-12-31","value":56.37,"profit":true},{"date":"2024-12-31","value":17.81,"profit":true}] |
| Gross Profit | 133.14M | 179.37M | 143.42M | 96.27M | 156.06M | [{"date":"2020-12-31","value":74.23,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":79.96,"profit":true},{"date":"2023-12-31","value":53.67,"profit":true},{"date":"2024-12-31","value":87,"profit":true}] |
| Gross Margin | 81.40% | 74.26% | 73.08% | 73.31% | 93.37% | [{"date":"2020-12-31","value":87.18,"profit":true},{"date":"2021-12-31","value":79.53,"profit":true},{"date":"2022-12-31","value":78.27,"profit":true},{"date":"2023-12-31","value":78.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 95.64M | 75.52M | 140.38M | 84.32M | 178.66M | [{"date":"2020-12-31","value":53.53,"profit":true},{"date":"2021-12-31","value":42.27,"profit":true},{"date":"2022-12-31","value":78.57,"profit":true},{"date":"2023-12-31","value":47.2,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | 37.50M | 103.85M | 3.04M | 11.94M | (22.61M) | [{"date":"2020-12-31","value":36.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":2.92,"profit":true},{"date":"2023-12-31","value":11.5,"profit":true},{"date":"2024-12-31","value":-21.77,"profit":false}] |
| Total Non-Operating Income/Expense | (55.55M) | (50.39M) | 33.22M | 57.99M | 30.14M | [{"date":"2020-12-31","value":-95.79,"profit":false},{"date":"2021-12-31","value":-86.88,"profit":false},{"date":"2022-12-31","value":57.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":51.97,"profit":true}] |
| Pre-Tax Income | 1.29M | 72.20M | 36.01M | 63.66M | 2.52M | [{"date":"2020-12-31","value":1.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":49.87,"profit":true},{"date":"2023-12-31","value":88.17,"profit":true},{"date":"2024-12-31","value":3.49,"profit":true}] |
| Income Taxes | (5.31M) | (4.15M) | 41.23M | 9.84M | 6.55M | [{"date":"2020-12-31","value":-12.87,"profit":false},{"date":"2021-12-31","value":-10.06,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":23.87,"profit":true},{"date":"2024-12-31","value":15.89,"profit":true}] |
| Income After Taxes | 6.60M | 76.35M | (5.22M) | 53.82M | (4.03M) | [{"date":"2020-12-31","value":8.64,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-6.84,"profit":false},{"date":"2023-12-31","value":70.49,"profit":true},{"date":"2024-12-31","value":-5.28,"profit":false}] |
| Income From Continuous Operations | (2.98M) | 57.59M | (5.22M) | 21.10M | (4.03M) | [{"date":"2020-12-31","value":-5.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-9.06,"profit":false},{"date":"2023-12-31","value":36.64,"profit":true},{"date":"2024-12-31","value":-7,"profit":false}] |
| Income From Discontinued Operations | (9.58M) | (19.21M) | (28.14M) | - | - | [{"date":"2020-12-31","value":-958300000,"profit":false},{"date":"2021-12-31","value":-1921500000,"profit":false},{"date":"2022-12-31","value":-2814200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (2.98M) | 57.14M | (33.36M) | 52.15M | (4.03M) | [{"date":"2020-12-31","value":-5.22,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-58.39,"profit":false},{"date":"2023-12-31","value":91.28,"profit":true},{"date":"2024-12-31","value":-7.06,"profit":false}] |
| EPS (Diluted) | 4.55 | 6.42 | 4.28 | 6.10 | 5.71 | [{"date":"2020-12-31","value":70.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.67,"profit":true},{"date":"2023-12-31","value":95.02,"profit":true},{"date":"2024-12-31","value":88.94,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| LGND | |
|---|---|
| Cash Ratio | 21.76 |
| Current Ratio | 24.69 |
| Quick Ratio | 24.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| LGND | |
|---|---|
| ROA (LTM) | 1.48% |
| ROE (LTM) | 5.42% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| LGND | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.36 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.64 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| LGND | |
|---|---|
| Trailing PE | 82.97 |
| Forward PE | 22.12 |
| P/S (TTM) | 14.69 |
| P/B | 3.81 |
| Price/FCF | 282 |
| EV/R | 13.50 |
| EV/Ebitda | 33.59 |
| PEG | 1.53 |
Ligand Pharmaceuticals Incorporated (LGND) share price today is $187.79
Yes, Indians can buy shares of Ligand Pharmaceuticals Incorporated (LGND) on Vested. To buy
Yes, you can purchase fractional shares of Ligand Pharmaceuticals Incorporated (LGND) via the Vested app. You can start investing in Ligand Pharmaceuticals Incorporated (LGND) with a minimum investment of $1.
You can invest in shares of Ligand Pharmaceuticals Incorporated (LGND) via Vested in three simple steps:
The 52-week high price of Ligand Pharmaceuticals Incorporated (LGND) is $212.49. The 52-week low price of Ligand Pharmaceuticals Incorporated (LGND) is $93.58.
The price-to-earnings (P/E) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 82.969
The price-to-book (P/B) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 3.81
The dividend yield of Ligand Pharmaceuticals Incorporated (LGND) is 0.00%
The market capitalization of Ligand Pharmaceuticals Incorporated (LGND) is $3.74B
The stock symbol (or ticker) of Ligand Pharmaceuticals Incorporated is LGND
Consider the share price of Ligand Pharmaceuticals Incorporated as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Ligand Pharmaceuticals Incorporated has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Ligand Pharmaceuticals Incorporated shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Ligand Pharmaceuticals Incorporated stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Ligand Pharmaceuticals Incorporated and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Ligand Pharmaceuticals Incorporated stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
